← Back to Screener
InMed Pharmaceuticals Inc. Common Shares (INM)
Price$0.72
Favorite Metrics
Price vs S&P 500 (26W)-75.30%
Price vs S&P 500 (4W)-22.65%
Market Capitalization$2.40M
All Metrics
Book Value / Share (Quarterly)$3.42
P/TBV (Annual)0.55x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)65.52%
Cash Flow / Share (Quarterly)$-2.65
Price vs S&P 500 (YTD)-37.16%
Gross Margin (TTM)29.73%
Net Profit Margin (TTM)-170.07%
EPS (TTM)$-4.08
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-4.08
EPS (Annual)$-8.36
ROI (Annual)-60.75%
Gross Margin (Annual)34.53%
Net Profit Margin (5Y Avg)-601.11%
Cash / Share (Quarterly)$2.50
Revenue Growth QoQ (YoY)-26.22%
ROA (Last FY)-52.39%
Revenue Growth TTM (YoY)-6.73%
EBITD / Share (TTM)$-2.89
ROE (5Y Avg)-110.59%
Operating Margin (TTM)-174.87%
Cash Flow / Share (Annual)$-3.88
P/B Ratio0.25x
P/B Ratio (Quarterly)0.31x
EV / Revenue (TTM)-1.01x
Net Interest Coverage (TTM)-32.43x
ROA (TTM)-62.04%
EPS Incl Extra (Annual)$-8.36
Current Ratio (Annual)6.99x
Quick Ratio (Quarterly)4.85x
3-Month Avg Trading Volume0.12M
52-Week Price Return-73.40%
Tangible BV / Share (Quarterly)$2.87
P/S Ratio (Annual)0.48x
Asset Turnover (Annual)0.32x
52-Week High$7.98
Operating Margin (5Y Avg)-624.99%
EPS Excl Extra (Annual)$-8.36
Tangible BV CAGR (5Y)19.79%
26-Week Price Return-66.56%
Quick Ratio (Annual)6.30x
13-Week Price Return-37.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.94x
Enterprise Value$-4.558
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-24.85%
Inventory Turnover (Annual)2.93x
Pretax Margin (Annual)-165.14%
Cash / Share (Annual)$5.55
3-Month Return Std Dev81.88%
Gross Margin (5Y Avg)33.37%
ROE (Last FY)-60.75%
Net Interest Coverage (Annual)-5.98x
EPS Basic Excl Extra (Annual)$-8.36
P/FCF (TTM)10.89x
Receivables Turnover (TTM)20.23x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.08
Receivables Turnover (Annual)12.09x
ROI (TTM)-73.64%
P/S Ratio (TTM)0.53x
Pretax Margin (5Y Avg)-600.98%
Revenue / Share (Annual)$5.06
Tangible BV / Share (Annual)$5.90
Price vs S&P 500 (52W)-108.49%
Year-to-Date Return-33.02%
5-Day Price Return-0.36%
EPS Normalized (Annual)$-8.36
ROA (5Y Avg)-84.67%
Net Profit Margin (Annual)-165.14%
Month-to-Date Return10.09%
Cash Flow / Share (TTM)$-2.20
EBITD / Share (Annual)$-7.89
Operating Margin (Annual)-160.77%
ROI (5Y Avg)-110.59%
EPS Basic Excl Extra (TTM)$-4.08
P/TBV (Quarterly)0.37x
P/B Ratio (Annual)0.48x
Inventory Turnover (TTM)3.09x
Pretax Margin (TTM)-170.07%
Book Value / Share (Annual)$6.71
Price vs S&P 500 (13W)-40.03%
Beta0.55x
P/FCF (Annual)23.96x
Revenue / Share (TTM)$1.14
ROE (TTM)-73.64%
52-Week Low$0.57
Analyst Recommendations
Nov 2022
Dec 2022
Jan 2023
Feb 2023
2.25
2.25
2.25
2.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INMInMed Pharmaceuticals Inc. Common Shares | 0.53x | -6.73% | 29.73% | — | $0.72 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
InMed Pharmaceuticals is a clinical-stage Canadian biopharmaceutical company developing small molecule therapies for rare diseases, with a pipeline including candidates for epidermolysis bullosa, glaucoma, and Alzheimer's disease. The company also operates BayMedica, a commercial segment producing rare cannabinoids for the health and wellness market.